関連する実験動画
Updated: Jul 17, 2026

05:37
Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
Published on: May 31, 2018
ハロタンへの多重曝露による肝機能への影響に関する制御された前向きな研究
Lancet (London, England)
|April 12, 1975
まとめ
ハロタン麻酔の再曝露は肝臓酵素を上昇させる可能性があります,特に前回のハロタン曝露が4回未満の患者で. この研究では,ハロタン (halothane) を調査した.
科学分野:
- アネステシオロジー アネステシオロジー
- 肝臓病理学 肝臓病理学
- クリニカル生化学 臨床生化学
背景:
- ハロタンは,広く使用されている揮発性麻酔剤です.
- 以前のハロタンへの曝露は,肝臓の不良反応のリスクを増やす可能性があります.
- 肝機能のモニタリングは,繰り返し麻酔を受けている患者にとって非常に重要です.
研究 の 目的:
- 繰り返しハロタン麻酔が肝臓機能に与える影響を調査する.
- 以前のハロタン曝露が肝臓損傷のリスクに影響するかどうかを判断する.
- ハロタンと対照麻酔薬を投与した患者の肝臓酵素濃度を比較する.
主な方法:
- ランダム化比較試験で,各グループで76人の患者が参加した.
- 患者はハロタンまたは対照麻酔剤 (ハロタンなしの器具) を投与された.
- 血清グルタミン酸オキシロ酸エステルトランスアミナーゼ (S.G.O.T.) 血圧レベルは,手術前および手術後の2〜3週間にわたって連続的に測定されました.
主要な成果:
- S.G.O.T.がかなり高くなった. 濃度が,対照群と比較して,ハロタン群で観察されました.
- 高いS.G.O.T.T.を掲げている. ハロタン濃度は,主に,前回のハロタン麻酔剤を4回未満服用した患者で観察されました.
- ハロタン群の1人の患者は肝細胞死滅を発症し,2人の患者はS.G.O.T.が上昇した. 再曝露の際には,再曝露の際には,再曝露を繰り返す.
結論:
- ハロタン麻酔に再曝露すると,肝臓酵素が上昇する可能性があります.
- 以前にハロタンに限られた曝露をした患者は,これらの効果に対してより感受性があるようです.
- ハロタンによる肝損傷に関するさらなる調査が必要である.
関連する概念動画
Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

